Market Overview

The global Cell-based Assay Market was valued at USD 24.1 Billion in 2024 and is forecast to reach USD 45.2 Billion by 2033. It is expected to grow at a CAGR of 6.88% during the forecast period from 2025 to 2033. Growth is driven by increasing demand for advanced drug discovery solutions, rising chronic disease prevalence, and the adoption of personalized medicine and innovative cell culture technologies.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Cell-based Assay Market Key Takeaways

• The global cell-based assay market was valued at USD 24.1 Billion in 2024.
• The market is expected to grow at a CAGR of 6.88% during 2025-2033.
• The forecast period for the market is 2025-2033.
• The rising adoption of cell-based assays for drug discovery, toxicology, and disease modeling is driving market growth.
• Increasing incidences of chronic diseases such as cancer, diabetes, and autoimmune disorders are creating growth opportunities.
• Emphasis on personalized medicine is accelerating the adoption of cell-based assays for tailored therapies.
• The integration of innovations like 3D cell cultures and high-throughput screening further boosts market expansion.

Sample Request Link: https://www.imarcgroup.com/cell-based-assays-market/requestsample

Market Growth Factors

The global cell-based assay market is driven by demand for novel therapies for chronic disease treatment. The globally active drug discovery & development system has been expanded and, as a result, a large number of drug candidates are being screened and evaluated using high throughput screening techniques. These assays can identify drug potency and toxicity, which greatly increases the efficiency of drug development, and the increasing interest in precision medicine requires a deeper knowledge of the interactions of cellular pathways. As such, cell-based assays are highly sought after for drug discovery in the current market.

Medicines that are personalized, treatments tailored to a patient's specific genetic, molecular, and cellular characteristics, are becoming common. Cell-based assays allow testing of the patient's cells to determine whether the treatment is likely to be effective, to reduce side effects, and to increase chances for treatments to succeed, while decreasing the costs from unnecessary treatments. The expanding focus toward personalized medicine is driving the demand for these assays in both clinical and research settings, thus driving the market.

Cell culture-based technologies are applied more, such as when developers create 3D cultures, tissue models, and organoids that mimic in vivo physiological conditions, so the market is expected to grow more. The availability of more accurate drug screening and toxicity testing using 3D cultures, organoids, and tissue models is projected to fuel market demand. Furthermore, the development of microfluidics and lab-on-a-chip systems has led to advanced miniaturized and automated technologies that provide a faster and more efficient means of drug discovery. Thus, driving the growth of the market.

Market Segmentation

Breakup by Product and Services:

• Consumables: Includes reagents and media, cells and cell lines, probes and labels. Consumables are essential disposable materials ensuring proper cell growth and enabling accurate, reproducible cell-based experiments, representing the largest market segment.
• Instruments: Comprise microplates, microplate readers, high throughput screening systems, and liquid handling systems.
• Services
• Software

Breakup by Technology:

• Automated Handling
• Flow Cytometry
• Label-Free Detection
• High-Throughput Screening: Dominates the market; used for automated, large-scale screening of compounds for biological activity in drug discovery.
• Others

Breakup by Application:

• Drug Discovery: The largest application segment; involves assessing drug delivery, efficacy, safety, targeted delivery, and toxicity using cell-based models.
• Basic Research
• ADME Studies
• Predictive Toxicology
• Others

Breakup by End-User:

• Pharmaceutical and Biotechnology Companies: Hold the largest market share; use assays for drug candidate validation, safety profiling, high-throughput screening, and quality control.
• Academic and Government Institutions
• Contract Research Organizations
• Others

Regional Insights

North America dominates the global cell-based assay market due to strong demand for advanced assay technologies and consumables. The region benefits from stringent regulatory standards and ongoing development of novel cell-based assay techniques. This focus on drug safety and technological innovation has positioned North America as the largest market, driving overall global growth.

Recent Developments & News

• In April 2025, EditCo Bio, Inc. entered into a strategic licensing agreement with Promega Corporation to integrate advanced bioluminescent technologies into CRISPR-engineered cell lines, enhancing assay precision and validation.
• In May 2025, NeoGenomics, Inc. launched its c-MET CDx immunohistochemistry assay for advanced non-small cell lung cancer, supporting precision treatment decisions with a 48-hour turnaround.
• In May 2025, Roche received FDA approval for its VENTANA MET (SP44) RxDx Assay, the first companion diagnostic identifying eligible NSQ-NSCLC patients for AbbVie’s Emrelis™ therapy.
• In May 2025, Caris Life Sciences adopted MET Immunohistochemistry testing as standard care for non-squamous NSQ-NSCLC patients to guide personalized therapies.
• In December 2021, Thermo Fisher Scientific Inc. completed its acquisition of PPD, Inc., expanding its clinical development service offerings.
• In March 2022, Promega Corporation and FUJIFILM Cellular Dynamics, Inc. collaborated to advance novel assay development combining bioluminescent reporter technology in iPSCs.
• In 2022, BD introduced the BD Rhapsody™ TCR/BCR Multiomic Assay, enhancing immune system cell analysis for various research areas.

Key Players

• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc
• Cell Biolabs, Inc.
• Cell Signaling Technology, Inc
• Charles River Laboratories
• Corning Incorporated
• DH Life Sciences, LLC
• Eurofins DiscoverX
• Lonza
• Merck KGaA
• Promega Corporation
• Thermo Fisher Scientific Inc

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization: https://www.imarcgroup.com/request?type=report&id=1079&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302